Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In-hospital mortality rates of critically ill COVID-19 patients in France: a nationwide cross-sectional study of 45 409 ICU patients

Antoine Guillon¹, Emeline Laurent²,³, Lucile Godillon², Antoine Kimmoun⁴ and Leslie Grammatico-Guillon²,⁵,*

¹Intensive Care Unit, Tours University Hospital, Research Center for Respiratory Diseases, INSERM U1100, University of Tours, Tours, France, ²Epidemiology Unit EpiDcliC, Service of Public Health, Tours University Hospital, Tours, France, ³Research Unit EA7505 (Education Ethique et santé), University of Tours, Tours, France, ⁴Teaching Hospital of Nancy, Intensive Care Unit, University of Lorraine, Nancy, France and ⁵MAVIVH, INSERM U1259, University of Tours, Tours, France

*Corresponding author. E-mail: leslie.guillon@univ-tours.fr

Keywords: COVID-19; hospital discharge; intensive care; mortality; outcome

Editor—We examined the temporal trend of in-hospital mortality of critically ill COVID-19 patients in France during the first year of the pandemic. We performed a cross-sectional, nationwide study, using data from the French Hospital Discharge Database (HDD). This database relies on the mandatory notification of each hospital stay, through a coded summary, for all public and private French hospitals. No nominative, sensitive, or personal data of patients were collected. Our study involved the reuse of previously recorded and anonymised data. The study falls within the scope of the French Reference Methodology MR-005 (declaration 2205437 v 0, 22 August 2018, subscribed by the Teaching Hospital of Tours), which requires neither information nor consent of the included individuals. This study was consequently registered with the French Data Protection Board (CNIL MR-005 #2018160620).

Patients were included according to the following criteria: adults (≥18 yr), admitted to an ICU between March 1, 2020 and March 14, 2021, with an ICD-10 diagnosis code of COVID-19.¹,² The following characteristics were considered: age, sex, Charlson Comorbidity Index,³,⁴ SAPS II (Simplified Acute Physiology Score II), invasive mechanical ventilation, and ICU length of stay. The outcome measure of interest was vital status at the end of the hospital stay. Deaths were assigned to the week of admission. To identify alteration in weekly mortality rates over the 12-month period, a linear regression model was performed using R, version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria); P<0.05 was considered statistically significant. No nominative, sensitive, or personal data were collected.

In France over the first year of the pandemic, 45 409 patients were admitted to ICU for COVID-19. Global patient characteristics were median (inter-quartile range): age 67 [57–74] yr; sex ratio male:female 2:3; Charlson Comorbidity Index 0: 41%, 1–2: 34%, ≥3: 25%; SAPS II 36 [27–46]; invasive mechanical ventilation 55%; ICU length of stay 9 [4–20] days; and global in-hospital mortality 31%. Trends in hospital presentation and in-hospital mortality are presented in Figure 1. Weekly mortality rate for patients hospitalised in ICU for COVID-19 remained constant throughout the first year of the pandemic (r²=0.009, P=0.50). Particular trends can be highlighted. A reduction of mortality rate appeared to be observed in the first weeks of the COVID-19 pandemic context: binational survey study. J Med Int Res 2020; 22, e19947

1. Hampton T, Crunkhorn R, Lowe N, et al. The negative impact of wearing personal protective equipment on communication during coronavirus disease 2019. J Laryngol Otol 2020; 134: 577–81
2. Spahr AJ, Dorman MF. Performance of subjects fit with the Advanced Bionics CII and Nucleus 3G cochlear implant devices. Arch Otolaryngol Head Neck Surg 2004; 130: 624–8
3. Parush A, Wacht O, Gomes R, Frenkel A. Human factor considerations in using personal protective equipment in the COVID-19 pandemic context: binational survey study. J Med Int Res 2020; 22, e19947
4. Bashford JA, Rienner KR, Warren RM. Increasing the intelligibility of speech through multiple phonemic restorations. Percept Psychophys 1992; 51: 211–7
5. Jones CPH, Fawker-Corbett J, Groom P, Morton B, Lister C, Mercer SJ. Human factors in preventing complications in anaesthesia: a systematic review. Anaesthesia 2018; 73: 12–24
6. Spahr AJ, Dorman MF, Litvak LM, et al. Development and validation of the AzBio sentence lists. Ear Hear 2012; 33: 112–7
pandemic surge (weeks 10–13, 2020). Meanwhile, a decreasing use of invasive ventilation support was observed in the same weeks. Weeks 19–30 (2020) should be interpreted with caution considering the low incidence of COVID-19 over the summer period. Changes were observed in the patient phenotype at that time: increased morbidities at presentation, lowest sex ratio, and peaks in mortality. Over the 12-month study period, age, SAPS II, and the use of invasive ventilation support were remarkably constant (except for weeks 10–13).

This study also has limitations. First, the use of administrative hospital databases introduced an inherent bias that must be considered. The strengths and limitations of using healthcare databases for epidemiological purposes have been extensively discussed. Briefly, the lack of granularity of the database could be a limiting factor, but conversely, it is an exhaustive real-life record of all patients hospitalised without initial selection bias. Second, patients were included up to March 14, 2021 and data were extracted on June 11, 2021. Consequently, missing discharge summary data are possible for patients with extremely long ICU length of stay occurring at the end of the study period, which could have biased the results of the last weeks. Last, these results are difficult to interpret without the number of cases in the general population. However, one has to keep in mind that detection of cases of COVID-19 was suboptimal at the beginning of the pandemic in the general population in France. The incidence rate in the general population would have represented an inconsistent indicator for the present study. We preferred to refer to ICU admissions for COVID-19 as a surrogate for the burden on the healthcare system.

We provide a national surveillance of all ICU patients with COVID-19 hospitalised during the first year of the pandemic in France. Despite an extraordinary year for science and a constant flow of new therapeutic strategies proposed during the study period, ICU outcome of COVID-19 patients was not improved.

Fig 1. COVID-19 patients hospitalised in ICU in France: 1-yr trend in clinical characteristics and in-hospital mortality rates. The purple line shows weekly mortality rates; blue histograms show the corresponding number of COVID-19 patients per week newly hospitalised in ICU (upper panel). Deaths were assigned to the week of admission. Clinical characteristics (six figures of the lower panel) are represented as median (with first and third inter-quartile ranges as dashed lines) or rate with a distribution of patients according to the Charlson Co-morbidity Index (Charlson CI) in three categories. ICU LOS, ICU length of stay; IMV, invasive mechanical ventilation; SAPS II, Simplified Acute Physiology Score II.
Acknowledgements

We thank all staff of healthcare facilities who contributed to the Hospital Discharge Database implementation. Restrictions apply to the availability of these data and so they are not publicly available. However, data are available from the authors upon reasonable request and with the permission of the institution.

Declarations of interest

The authors declare that they have no conflicts of interest.

References

1. Guillon A, Laurent E, Godillon L, Kimmoun A, Grammatico-Guillon L. Inter-regional transfers for pandemic surges were associated with reduced mortality rates. Intensive Care Med 2021; 47: 798–800
2. Guillon A, Laurent E, Godillon L, Kimmoun A, Grammatico-Guillon L. Long-term mortality of elderly patients after intensive care unit admission for COVID-19. Intensive Care Med 2021; 47: 710–2
3. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173: 676–82
4. D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49: 1429–33
5. Jouan Y, Grammatico-Guillon L, Espitalier F, Cazals X, François P, Guillon A. Long-term outcome of severe herpes simplex encephalitis: a population-based observational study. Crit Care 2015; 19: 345
6. Sunder S, Grammatico-Guillon L, Baron S, et al. Clinical and economic outcomes of infective endocarditis. Infect Dis (Lond) 2015; 47: 80–7
7. Guillon A, Hermetet C, Barker KA, et al. Long-term survival of elderly patients after intensive care unit admission for acute respiratory infection: a population-based, propensity score-matched cohort study. Crit Care 2020; 24: 384
8. Puliano G, Di Domenico L, Sabbatini CE, et al. Under-detection of cases of COVID-19 in France threatens epidemic control. Nature 2021; 590: 134–9

Sepsis in severe COVID-19 is rarely septic shock: a retrospective single-centre cohort study

Pietro Arina1, Valeria Moro1, Beatrice Baso1, Christopher Baxter-Derrington2 and Mervyn Singer1,*

1Bloomsbury Institute of Intensive Care Medicine, Division of Medicine, University College London, London, UK and
2Health Intelligence, Medicine Board, University College London Hospitals NHS Foundation Trust, London, UK

*Corresponding author. E-mail: m.singer@ucl.ac.uk

Keywords: COVID-19; hyperlactataemia; sepsis; sepsis-3; septic shock

Editor—Severe COVID-19 fulfills both the Sepsis-3 definition of sepsis, namely life-threatening organ dysfunction attributable to a dysregulated host response to infection and the clinical criteria of a rise in Sequential Organ Failure Assessment (SOFA) score ≥2 points above the patient’s existing baseline.1 We observed in our cohort of patients requiring intensive care admission that few had hyperlactataemia despite significant hypoxaemia. The Sepsis-3 definition of septic shock identifies a subset in whom profound circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than with sepsis alone. Clinical criteria for shock include an MAP <65 mm Hg and serum lactate level >2 mM in the absence of hypovolaemia.1 This observation suggests that SARS-CoV-2 does not, in general, trigger significant cellular metabolic dysfunction. Sepsis and acute respiratory distress syndrome represent umbrella syndromes containing multiple sub-phenotypes with relatively distinct clinical or biological signatures and differing outcomes.2,3 Using latent class analysis, similar findings have also been applied to large population cohorts with COVID-19.4,5 Currently, only one small study of 18 patients hospitalised with COVID-19 has focused on hyperlactataemia, but did not report associations with the degree of hypoxaemia or vasopressor use.6 We thus sought to assess the frequency of hyperlactataemia in patients with COVID-19 admitted to intensive care and receiving vasopressors, and the relationship to hypoxaemia and commencement of vasopressors.

Data were retrospectively extracted from the hospital’s EPIC (Verona, WI, USA) electronic healthcare record system for intensive care patients with a primary or secondary Intensive Care National Audit & Research Centre admission code of community-acquired pneumonia from March 2019 to February 2021. These included patient characteristics, organ function, and blood gas measurements (including lactate,